Environmental Exposure and Cardiometabolic Disease

环境暴露与心血管代谢疾病

基本信息

  • 批准号:
    10354688
  • 负责人:
  • 金额:
    $ 218.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-01 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY (Overall) This proposal is to continue to grow and expand the University of Louisville Superfund Center established in 2017. Currently, the Center supports research on the cardiometabolic effects of volatile organic chemicals (VOCs) that are of high relevance to the Superfund Program. Center investigators conduct mode-of-action research to unravel critical pathways of toxicity and to identify toxicological end-points (cardiometabolic changes) of chemicals (VOCs) found at Superfund and related sites. Using high throughput mass spectrometry and an innovative suite of mechanism-based biomarkers, animal experiments and human population studies, Center investigations have contributed to the discovery and validation of novel biomarkers of both exposure and cardiometabolic injury that would lay the foundation for future remediation strategies. These studies employ state-of-the-art tools to develop pollutant atmospheres for animal exposure and to measure unique and sensitive biological endpoints reflective of cardiometabolic injury. In addition, work supported by the Center is leading to the development of new methods and devices for quantifying atmospheric levels of VOCs that employ advanced technologies and offer precise, but low-cost measurements of hazardous waste sites. As before, the major objectives of the Center are to conduct state-of-the-art research on the cardiometabolic toxicity of VOCs and to determine how they affect cardiometabolic disease (CMD) prevalence and severity in exposed populations. These studies will be complemented by mode-of-action mechanistic studies in animals to identify the molecular and cellular mechanisms that contribute to VOC toxicity. The findings of these studies will continue to contribute to both the discovery and the validation of sensitive and robust biomarkers that could be used to assess the extent of exposure, metabolism and toxicity. Center investigators are creating new technologies for detecting VOCs at low environmental levels to enable future exposure assessment activities. Senior Center members educate and train junior investigators, graduate students and post-doctoral Fellows in the field of environmental science, and promote relevant community awareness and participation to enhance mutual bidirectional understanding of exposure risk and the health effects of exposure. The findings and discoveries of the Center will be transferred to affected communities, end users in public and private sectors, and other stakeholders. For future use and analysis, all samples of human and animal tissues and all data collected during Center investigations will be stored in a computer-coded biorepository. Collectively, expansion and growth of the Center activities will enhance its contribution and lead to rigorous evaluation and better understanding of the effects of these hazardous chemicals on obesity, diabetes and cardiovascular disease.
项目概要(总体) 这项建议是继续发展和扩大路易斯维尔大学超级基金中心成立于 2017.目前,该中心支持挥发性有机化学品对心脏代谢影响的研究 (VOC)与超级基金计划高度相关。研究中心研究者开展行动模式 研究以阐明毒性的关键途径并确定毒理学终点(心脏代谢变化) 在超级基金和相关场所发现的化学品(VOC)。使用高通量质谱和 基于机制的生物标志物、动物实验和人群研究的创新套件,中心 研究有助于发现和验证暴露和 这将为未来的补救策略奠定基础。这些研究采用 最先进的工具,用于开发动物暴露的污染物大气,并测量独特和敏感的 反映心脏代谢损伤的生物学终点。此外,该中心支持的工作正在导致 开发新的方法和设备,用于量化大气中的VOC水平, 技术,并提供精确的,但低成本的测量危险废物场地。和以前一样,少校 该中心的目标是对VOCs的心脏代谢毒性进行最先进的研究, 确定它们如何影响暴露人群中心脏代谢病(CMD)的患病率和严重程度。 这些研究将通过动物中的作用机制研究来补充,以确定分子 以及导致VOC毒性的细胞机制。这些研究的结果将继续有助于 发现和验证敏感和强大的生物标志物,可用于评估 接触程度、代谢和毒性。中心的研究人员正在创造新的技术, 低环境水平的挥发性有机化合物,以使未来的接触评估活动。高级中心成员 教育和培训环境领域的初级调查员、研究生和博士后研究员 科学,并促进相关社区的认识和参与,以加强相互双向 了解暴露风险和暴露对健康的影响。该中心的发现和发现 将转移到受影响社区、公共和私营部门的最终用户以及其他利益攸关方。为 未来的使用和分析,所有人类和动物组织样本以及中心期间收集的所有数据 调查结果将储存在计算机编码的生物储存库中。总的来说,中心的扩大和发展 这些活动将加强其贡献,并导致严格评价和更好地了解 这些有害化学物质对肥胖、糖尿病和心血管疾病的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sanjay Srivastava其他文献

Sanjay Srivastava的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sanjay Srivastava', 18)}}的其他基金

Atherogenic Mechanisms of Electronic Nicotine Delivery Systems
电子尼古丁输送系统的致动脉粥样硬化机制
  • 批准号:
    9917380
  • 财政年份:
    2020
  • 资助金额:
    $ 218.9万
  • 项目类别:
Atherogenic Mechanisms of Electronic Nicotine Delivery Systems
电子尼古丁输送系统的致动脉粥样硬化机制
  • 批准号:
    10533743
  • 财政年份:
    2020
  • 资助金额:
    $ 218.9万
  • 项目类别:
Atherogenic Mechanisms of Electronic Nicotine Delivery Systems
电子尼古丁输送系统的致动脉粥样硬化机制
  • 批准号:
    10317034
  • 财政年份:
    2020
  • 资助金额:
    $ 218.9万
  • 项目类别:
Atherogenic Mechanisms of Electronic Nicotine Delivery Systems
电子尼古丁输送系统的致动脉粥样硬化机制
  • 批准号:
    10082463
  • 财政年份:
    2020
  • 资助金额:
    $ 218.9万
  • 项目类别:
Pathology and Bio-analytics Core
病理学和生物分析核心
  • 批准号:
    10452735
  • 财政年份:
    2018
  • 资助金额:
    $ 218.9万
  • 项目类别:
Pathology and Bio-analytics Core
病理学和生物分析核心
  • 批准号:
    10208901
  • 财政年份:
    2018
  • 资助金额:
    $ 218.9万
  • 项目类别:
Project 2 - Molecular and Cellular Mechanisms of Cardiometabolic Toxicity of VOCs
项目2——VOCs心脏代谢毒性的分子和细胞机制
  • 批准号:
    10693804
  • 财政年份:
    2017
  • 资助金额:
    $ 218.9万
  • 项目类别:
KC Donnelly Externship–Promotion of Translational/Transdisciplinary Efforts in Graduate & Post-Doctoral Research
KC Donnelly 实习 — 促进研究生的转化/跨学科努力
  • 批准号:
    10382018
  • 财政年份:
    2017
  • 资助金额:
    $ 218.9万
  • 项目类别:
Environmental Exposure and Cardiometabolic Disease
环境暴露与心血管代谢疾病
  • 批准号:
    9904675
  • 财政年份:
    2017
  • 资助金额:
    $ 218.9万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10354693
  • 财政年份:
    2017
  • 资助金额:
    $ 218.9万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 218.9万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 218.9万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 218.9万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 218.9万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 218.9万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 218.9万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 218.9万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 218.9万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 218.9万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 218.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了